---
document_datetime: 2025-06-12 11:53:30
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rybrevant-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: rybrevant-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.6119041
conversion_datetime: 2025-12-28 14:21:49.076432
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rybrevant

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------|
| X/0014               | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration | 30/01/2025                          | 04/04/2025                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion Rybrevant EMEA/H/C/005454/X/014. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0018/G   | This was an application for a group of variations.   | 13/03/2025   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                     | variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                     |            |            |             |                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------|
| PSUSA/10977 /202405 | Periodic Safety Update EU Single assessment - amivantamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/01/2025 | n/a        |             | PRAC Recommendation - maintenance                                      |
| II/0013             | Extension of indication to include amivantamab in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (EGFRm NSCLC), based on results from study 73841937NSC3003 (MARIPOSA). This is a randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC. The primary objective of the MARIPOSA study was to assess the efficacy of the combination | 14/11/2024 | 19/12/2024 | SmPC and PL | Please refer to Scientific Discussion 'Rybrevant-H-C- 005454-II-0013'. |

<div style=\"page-break-after: always\"></div>

|           | of amivantamab and lazertinib (Arm A), compared with osimertinib (Arm B), as measured by PFS assessed by BICR in adult participants with EGFRm NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.2 of the EU RMP has also been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                    |            |            |             |                                                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------|
| IB/0017/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                | 30/09/2024 | n/a        |             |                                                                  |
| II/0011   | Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI) for RYBREVANT, based on the final results from study 61186372NSC3002 (MARIPOSA 2); this is a randomized, open label, multicenter Phase 3 study | 25/07/2024 | 22/08/2024 | SmPC and PL | Please refer to Scientific Discussion Rybrevant-H-C-5454- II-11. |

<div style=\"page-break-after: always\"></div>

|         | that compares efficacy and safety of amivantamab in combination with carboplatin and pemetrexed (ACP) with carboplatin and pemetrexed (CP). The primary objective of the MARIPOSA 2 study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the EU RMP has also been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                  |            |            |                       |                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------|
| II/0010 | Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations for RYBREVANT, based on the final results from study 61186372NSC3001 listed as a Specific Obligation in the Annex II of the Product Information; this is a global, open-label, randomized Phase 3 study of ACP compared to CP alone in participants with newly diagnosed, locally advanced or metastatic NSCLC characterized by EGFR exon 20ins. The primary objective of the PAPILLON study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package | 25/04/2024 | 27/06/2024 | SmPC, Annex II and PL | Please refer to Scientific Discussion: Rybrevant-H-C-5454- II-0010. |

<div style=\"page-break-after: always\"></div>

|                     | Leaflet is updated in accordance. Version 3.1 of the RMP has also been agreed. In addition, the MAH took the opportunity to update Annex II and Annex IV of the PI. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation given the fulfilment of the SOB. As part of the application, the MAH also requested an extension of the market protection by one additional year. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10977 /202311 | Periodic Safety Update EU Single assessment - amivantamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/06/2024 | n/a        |             | PRAC Recommendation - maintenance |
| PSUSA/10977 /202305 | Periodic Safety Update EU Single assessment - amivantamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/01/2024 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0009/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                           | 20/09/2023 | 16/05/2024 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

| R/0007              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/07/2023   | 11/09/2023   |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10977 /202211 | Periodic Safety Update EU Single assessment - amivantamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/06/2023   | n/a          |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10977 /202205 | Periodic Safety Update EU Single assessment - amivantamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/01/2023   | n/a          |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0004             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/11/2022   | n/a          |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0005             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29/11/2022   | 11/09/2023   | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0002              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/07/2022   | 26/09/2022   |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0001             | Update of section 4.8 of the SmPC in order to add hypokalaemia and hypomagnesaemia to the list of adverse drug reactions (ADRs), with the frequency common, based on an updated analysis of data submitted during the marketing authorisation procedure. The Package Leaflet is updated accordingly. In addition, the MAH proposed to update the current information in section 4.2 of the SmPC to improve clarity and provide more specific guidance. Section 4.4 was updated to also reflect ILD-like adverse reactions. The MAH also took the opportunity to introduce editorial changes in section 4.8 of the SmPC. | 07/07/2022   | 26/09/2022   | SmPC and PL       | Section 4.8 of the SmPC has been updated to add hypokalaemia and hypomagnesaemia to the list of adverse drug reactions (ADRs), with the frequency common, based on a reanalysis of data submitted during the initial marketing authorisation procedure. Section 4.2 of the SmPC has been updated to clarify recommendations for dose reductions. Sections 4.2 and 4.4 of the SmPC were harmonized to reflect consistently ILD and ILD-like reactions. In addition, examples of Grade 4 skin reactions were removed from section 4.2 of the SmPC. Finally, in Section 4.8 of the SmPC, the word 'paronychia' has been replaced by 'nail toxicity'. For more information, please |

<div style=\"page-break-after: always\"></div>

| C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | refer to the Summary of Product Characteristics.   |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|